1215010-54-0

Basic information

• Product Name: 2,6-dichloro-4-(6-(piperazin-1-yl)pyridin-3-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
• Synonyms: 2,6-dichloro-4-(6-(piperazin-1-yl)pyridin-3-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide
• CAS NO: 1215010-54-0
• Molecular Weight: 495.433
• Mol File: 1215010-54-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2,6-dichloro-4-(6-(piperazin-1-yl)pyridin-3-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dichloro-4-(6-(piperazin-1-yl)pyridin-3-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide(1215010-54-0)
• EPA Substance Registry System: 2,6-dichloro-4-(6-(piperazin-1-yl)pyridin-3-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide(1215010-54-0)

Safety Data

• Hazardous Substances Data: 1215010-54-0(Hazardous Substances Data)

Upstream product

• 351003-54-8 4-bromo-2,6-dichlorobenzenesulfonyl chloride 
• 1215013-78-7 2,6-dichloro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide 
• 73406-97-0 5-bromo-2-(piperazin-1-yl)pyridine 
• 1215009-29-2 4-bromo-2,6-dichloro-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide 
• 871125-86-9 1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine 
• 28466-21-9 1,3,5-trimethyl-1H-pyrazol-4-amine 

Relevant articles and documents

Discovery of a novel class of orally active trypanocidal N-Myristoyltransferase inhibitors

N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1) to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC50 = 2 nM) and T. brucei (EC50 = 2 nM) in culture. The compound has good oral pharmacokinetics and cures rodent models of peripheral HAT infection. This compound provides an excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead for further optimization.